• Biodexa Pharmaceuticals enrolled 112 of 168 planned participants in its Phase 3 Serenta trial of eRapa for familial adenomatous polyposis.
• A futility analysis could occur in early 2027, with database lock and topline results potentially due around year-end, sooner than originally expected.
• The planned Phase 1a trial of MTX240 for treatment-resistant gastrointestinal stromal tumors is expected to begin recruiting in South Korea in mid-2027.
• A Phase 1b dose-optimization study will follow immediately, aiming to identify a tolerable dose with evidence of efficacy.
• A pre-IND meeting with the FDA is scheduled for December 10, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090830PRIMZONEFULLFEED1001302591) on November 09, 2026, and is solely responsible for the information contained therein.